Novartis Vaccines & Diagnostics, Gmbh

Chiron Corporation

Glaxosmithkline Biologicals Sa

Ospedale San Raffaele S.r.l.

Roberto Petracca

Cesira Galeotti

Giuliano Bensi

Catherine Greer

Daniela Tornese Buonamassa

Vega Masignani

Maria Scarselli

Alessandra Bragonzi

Beatriz Alcala′ Franco

Irene Bianconi

Beatriz Alcala' Franco

An effectivevaccine may require one or several antigenic components, and so various antigens ofare identified for use in immunization. These polypeptides may optionally be used in combination with other nosocomial antigens.

[object Object]

Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production of conformational antibodies against both L1 proteins upon administration to mice.

Method for producing yeast expressed HPV types 6 and 16 capsid proteins

Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production conformational antibodies against both L1 proteins upon administration to mice.

Growing community of inventors

Siena, Italy

Roberto Petracca